Rodman & Renshaw Provides Color on BioCryst Pharmaceuticals

Rodman & Renshaw provided color on BioCryst Pharmaceuticals

, following a conversation with Dr. Robert Terkeltaub. In a research report published today, Rodman & Renshaw commented on the rise of prevalence of gout among the elderly population in the United States. In the report, the rating agency states, “According to latest estimates, the incidence and prevalence of gout has more than doubled in the last few decades in the US, with over 8 MM adults in the nation currently suffering from gout. The highest rise in incidence and prevalence has been in those individuals over the age of 65 and gout is particularly prevalent in the 75 and over population. These elderly patients are challenging because they present with a range of co-morbidities, including diabetes, high blood pressure, obesity, chronic kidney disease, and congestive heart failure, which frequently are present in combination. New therapies are required to treat gout because many of the drugs in the gout armament are old and very non-selective.” At the moment, Rodman & Renshaw have a Market Outperform rating and a price target on $7 placed on the company's stock. On Friday, BioCryst lost 1.05% of its value to finish the day at $3.78.